Chiron Shareholders Approve Novartis Offer

Biotechnology company Chiron Corp. said that its shareholders had approved an offer from Swiss drug maker Novartis to acquire all remaining shares of the company for $48 a share, or about $5.4 billion.

Chiron expects the acquisition to close today.